Very late relapse in diffuse large B-cell lymphoma represents clonally related disease and is marked by germinal center cell features

Blood

Volumn 102, Issue 1, 2003, Pages 324-327

  De Jong, Daphne ^a   Glas, Annuska M ^b   Boerrigter, Lucie ^b   Hermus, Marie Christine ^b   Dalesio, Otilia ^b   Willemse, Els ^b   Nederlof, Petra M ^b   Kersten, Marie Jose ^b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRIAMYCIN VP 16; BLEOMYCIN; CISPLATIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IMMUNOGLOBULIN HEAVY CHAIN; METHOTREXATE; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; VIMENTIN; VINBLASTINE; VINCRISTINE;

ADULT; AGE; AGED; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLONING; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE TRANSLOCATION; GERM CELL; GERMINAL CENTER; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN VARIABLE REGION; LARGE CELL LYMPHOMA; LYMPH NODE METASTASIS; MALE; MULTIMODALITY CANCER THERAPY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SECOND CANCER;

EID: 0037564796     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-09-2822     Document Type: Article

References (23)

1. The International Non-Hodgkin's lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. New Engl J Med. 1993;329:987-994.
2. Fisher F, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with tree intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma N Engl J Med. 1993;328:1002-1006.
3. Lee AYY, Connors JM, Klimo P, O'Reilly SE, Gascoyne RD. Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B. J Clin Oncol. 1997;15:1745-1753.
4. Cabanillas F, Velasquez WS, Hagemeister FB, McLaughlin P, Redman JR. Clinical, biologic and histologic features of late relapse in diffuse large cell lymphoma. Blood. 1992;79:1024-1028.
5. Lasota J, Nordling S, Mietitnen M. Testicular diffuse large B-cell lymphoma with tubular preservation: molecular genetic evidence of transformation from previous follicular lymphoma. Vichows Arch. 2000;436:276-283.
6. Nishiuchi R, Yoshino T, Teramoto N, et al. Clonal analysis by polymerase chain reaction of B-cell lymphoma with late relapse: a report of five cases. Cancer. 1996;77:757-762.
7. Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and genetics of tumours of the hematopoietic and lymphoid tissues. WHO Classification of Tumours. Lyon, France: IARC Press; 2001.
8. de Jong D, van Gorp J, Sle-Go DMDS, van Heerde P. T-cell rich B-cell non-Hodgkin's lymphoma: a progressed form of follicle center cell lymphoma and lymphocyte predominance Hodgkin's disease. Histopathology. 1996;28:15-24.
9. Liu J, Johnson RM, Traweek ST. Rearrangement of the BCL-2 gene in follicular lymphoma: detection by PCR in both fresh and fixed tissue samples. Diagn Mol Pathol. 1993;2:241-247.
10. van Eeden S, Nederlof PM, Taal BG, Offerhaus GJA, van Velthuysen MLF. A tumour with a neuroendocrine and papillary serous component: two or a pair? J Clin Pathol. 2002;55:710-714.
11. Fang JM, Finn WG, Hussong JW, Goolsby CL, Cubbon AR, Vaiakojis D. CD10 antigen expression correlates with the t(14;18)(q32;q21) major breakpoint region in diffuse large B-cell lymphoma. Mod Pathol. 1999;12:295-300.
12. Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood. 2002;99:1136-1143.
13. Levy R, Levy S, Cleary ML, et al. Somatic mutation in human B-cell tumors. Imm Rev. 1987;96:43-58.
14. Ottensmeier CH, Thompsett AR, Zhu D, Wilkins BS, Sweetenham JW, Stevenson FK. Analysis of VH genes in follicular and diffuse lymphoma shows ongoing somatic mutation and multiple isotype transcripts in early disease with changes during disease progression. Blood. 1998;91:4292-4299.
15. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.
16. Rosenwald A, Wright G, Chan W, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. New Engl J Med. 2002;346:1937-1947.
17. Lossos IS, Alizadeh AA, Eisen MB, Chan WC, Brown PO, Botstein D. Ongoing somatic immunoglobulin mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci U S A. 2000;97:10209-10213.
18. Huang JZ, Sanger WG, Greiner TC, et al. The t(14;18) defines a unique subset of diffuse large-cell lymphoma with a germinal center B-cell gene expression profile. Blood. 2002;99:2285-2290.
19. Kluin PM, van Krieken JH, Kleiverda K, Kluin-Nelemans JC. Discordant morphologic characteristics of B-cell lymphomas in bone marrow and lymph node biopsies. Am J Clin Pathol. 1990;94:59-66.
20. Kramer MHH, Hermans J, Parker J, et al. The clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population based study in 372 patients. J Clin Oncol. 1996;14:2131-2138.
21. Hill ME, McLennan KA, Cunningham DO, et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: British National Lymphoma Investigation Study. Blood. 1996;88:1046-1051.
22. Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of bcl-2 protein expression and bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood. 1997;90:244-251.
23. Kramer MHH, Hermans J,Wijburg E, et al. Clinical relevance of BCL2, BCL6 and MYC rearrangements in diffuse large B-cell lymphoma. Blood. 1998;92:3152-3162.